Neuropace, Inc. (NPCE)
NPCE moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How NPCE actually reacts to news — the realized, point-in-time move the market made, measured across 336 labeled events over the last three years with zero look-ahead.
NPCE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 326 |
| 30-min | 0.00% | 49% | 332 |
| 60-min | 0.00% | 48% | 333 |
| to close | 0.00% | 49% | 334 |
| Middle 50% of NPCE reactions | -1.45% to +1.35% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 336 |
Half of all Neuropace, Inc. news events land between -1.45% and +1.35% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NPCE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -0.92% | 44% | -1.64% |
| Rating reiterations | 43 | +0.24% | 56% | -1.08% |
| Price-target raises | 16 | +0.29% | 63% | -0.61% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how NPCE ranks against every other measured name →
That’s how NPCE usually reacts — get an email when it moves on news →Email me when NPCE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NPCE's baseline. Nothing else.
Recent NPCE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NeuroPace to Participate in 2026 Cantor Global Healthcare Conference | Press release | Business Wire | -0.47% | +2.98% | |
| NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference | Press release | Business Wire | +0.92% | +0.27% | |
| Form 10-Q NeuroPace Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.25% | +2.83% | |
| Form 8-K NeuroPace Inc For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +2.83% | |
| NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance | Press release | Business Wire | +0.25% | +2.83% | |
| Form 8-K NeuroPace Inc For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -6.58% | |
| NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy | Press release | Business Wire | +0.89% | -6.58% | |
| Form 8-K NeuroPace Inc For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.59% | +1.66% | |
| NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care | Press release | Business Wire | +0.63% | -4.89% | |
| NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | Press release | Business Wire | +0.63% | -4.89% | |
| Form 10-Q NeuroPace Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -7.96% | +6.61% | |
| Form 8-K NeuroPace Inc For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -7.96% | +6.61% | |
| NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance | Press release | Business Wire | -7.96% | +6.61% | |
| NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 | Press release | Business Wire | +0.48% | +0.78% | |
| NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 | Press release | Business Wire | -0.59% | +2.50% | |
| Form ARS NeuroPace Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.79% | +2.97% | |
| Form DEF 14A NeuroPace Inc For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.79% | +2.97% | |
| NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | -0.14% | +3.98% | |
| NeuroPace to Present at the Leerink Global Healthcare Conference | Press release | Business Wire | -1.19% | +4.00% | |
| Form 10-K NeuroPace Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.79% | -9.88% | |
| Form 8-K NeuroPace Inc For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -9.88% | |
| Form S-8 NeuroPace Inc | SEC filing · Form S-8 | SEC EDGAR | -1.79% | -9.88% | |
| NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook | Press release | Business Wire | -1.79% | -9.88% | |
| NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 | Press release | Business Wire | +0.04% | +2.61% | |
| NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook | Press release | Business Wire | -3.89% | -9.13% | |
| NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.07% | -0.07% | |
| NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy | Press release | Business Wire | -0.34% | -2.31% | |
| NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy | Press release | Business Wire | +0.00% | +0.12% | |
| NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting | Press release | Business Wire | +0.19% | +1.91% | |
| NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services | Press release | Business Wire | +0.00% | +12.60% | |
| Form 10-Q NeuroPace Inc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.59% | +11.61% | |
| Form 8-K NeuroPace Inc For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -5.59% | +11.61% | |
| NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | Press release | Business Wire | -5.59% | +11.61% | |
| NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025 | Press release | Business Wire | +0.74% | +0.56% | |
| NeuroPace to Participate in Upcoming Healthcare Conferences | Press release | Business Wire | -0.78% | +1.56% | |
| Form 10-Q NeuroPace Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -9.38% | +4.13% | |
| Form 8-K NeuroPace Inc For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -9.38% | +4.13% | |
| NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | Press release | GlobeNewswire | -9.38% | +4.13% | |
| NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases | Press release | GlobeNewswire | -0.59% | +6.39% | |
| NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 | Press release | GlobeNewswire | +0.00% | -0.68% | |
| Form 8-K NeuroPace Inc For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | +4.24% | |
| NeuroPace Announces Strategic CFO Transition | Press release | GlobeNewswire | +1.28% | +4.24% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.18% | -0.72% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.39% | -4.34% | |
| Form 8-K NeuroPace Inc For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -0.36% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.46% | -8.79% | |
| NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.39% | +0.78% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | -0.45% | |
| Form 8-K NeuroPace Inc For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +0.83% | |
| NeuroPace Secures Up to $75 Million in Debt Financing | Press release | GlobeNewswire | -0.23% | +0.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NPCE section they belong to.
Where else NPCE is measured.
NPCE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Neuropace, Inc.'s median reaction calculated?
Every labeled NPCE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 336 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of NPCE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does NPCE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.